Last updated: February 13, 2026
What Is the Current Market Status of NDC 00597-0042?
NDC 00597-0042 refers to Pemetrexed Injection, a chemotherapeutic agent used primarily for non-small cell lung cancer (NSCLC) and mesothelioma. The drug is marketed by Eli Lilly and Company under the brand name Alimta. As of 2023, the drug maintains a significant role in oncology treatment regimens, supported by robust sales figures and extensive clinical use.
Global sales for Pemetrexed in 2022 reached approximately $2.2 billion, with the U.S. accounting for roughly 65% of this revenue. The drug’s market penetration is driven by its approval status, clinical efficacy, and the increasing prevalence of NSCLC and mesothelioma. The drug is marketed as both a monotherapy and in combination with platinum-based agents.
How Competitive Is the Market for Pemetrexed?
The market for Pemetrexed faces competition from generic formulations. Since patent expiration in 2019, multiple manufacturers have launched biosimilar or generic versions, reducing prices and expanding availability.
Major competitors include:
- Sandoz (Novartis division): Launched a biosimilar version in late 2020.
- Teva Pharmaceuticals: Launched an authorized generic in 2021.
- Other generic manufacturers: Gained market share due to regulatory approvals in various countries.
Market share for branded Alimta has declined from over 80% in 2018 to approximately 50% in 2023, indicating a shift toward generics. Despite this, branded Pemetrexed retains a premium price point, especially in markets with limited generic access.
What Are the Price Trends and Projections?
Current Pricing
In the U.S., the average wholesale price (AWP) for a 500 mg vial of Pemetrexed is approximately $370. After discounts, actual transaction prices tend to be 20-30% lower.
Pricing Dynamics Post-Patent
- Pre-2019: The branded drug's price ranged from $370 to $400 per 500 mg vial.
- Post-2019: Introduction of generics led to a 30-40% reduction in prices for new shipments.
Future Price Trends
Analysts project continued price reductions for generic Pemetrexed due to increased competition. Prices for biosimilars and generics are expected to settle around $250-$300 per 500 mg vial within the next 2-3 years. However, branded Alimta may maintain higher prices in specific regions or for formulary reasons, with premiums of 10-20%.
Market Penetration and Pricing Impact
As biosimilars gain regulatory approval in the EU, U.S., and emerging markets, price expectations reflect a downward trend. In some markets, government negotiations and reimbursement policies could push generic prices below $250.
What Are the Revenue and Market Share Projections?
| Year |
Estimated Total Market (USD Billion) |
Pemetrexed Market Share |
Branded Versus Generic Revenue |
| 2023 |
$2.5 |
55% (branded + generics) |
Branded (~$1.2B), Generics (~$1.3B) |
| 2025 |
$3.0 |
45% (generic increase) |
Branded (~$0.9B), Generics (~$2.1B) |
| 2030 |
$3.5 |
35% (further generic uptake) |
Branded (~$0.6B), Generics (~$2.9B) |
Market share shifts depend on regulatory approvals and pricing pressures.
How Do Development Pipelines and Regulatory Approvals Impact Pricing?
Several biosimilars for Pemetrexed are in late-stage development, with some already approved in Europe and Canada. Their entry into the U.S. is anticipated over the next 1-2 years, intensifying competition and further depressing prices.
Innovations such as combination therapies and personalized medicine could impact Pemetrexed’s usage. However, as of 2023, no major recent patent filings suggest new formulations or indications that could extend exclusivity or maintain premium prices.
Key Takeaways
- Pemetrexed injection faces significant generic competition post-2019, resulting in lower average prices.
- By 2025, generic formulations are projected to comprise over 50% of the global Pemetrexed market.
- Prices are expected to stabilize around $250-$300 per 500 mg vial, with branded formulations maintaining a premium in certain regions.
- The expanding biosimilar pipeline and regulatory approvals could accelerate downward price pressures before 2025.
- Market revenue is expected to grow modestly, mainly driven by increased global adoption, even as per-unit prices decline.
Frequently Asked Questions
1. How does the entry of biosimilars influence Pemetrexed prices globally?
Biosimilar approvals in Europe, Canada, and Australia have caused prices to drop by approximately 30-40%. U.S. biosimilar approvals are anticipated over the next 1-2 years, which could lead to further price reductions.
2. What factors could sustain higher prices for Pemetrexed?
Limited biosimilar penetration in certain markets, formulary preferences, and clinical protocols favoring branded formulations can sustain higher prices for Alimta.
3. Are there upcoming patent expirations affecting Pemetrexed?
The primary patent expired in 2019. Ongoing patent filings for new formulations or delivery methods are limited, so no significant patent exclusivity extensions are expected.
4. How do payer negotiations impact Pemetrexed pricing?
Negotiated discounts and formulary placements significantly influence actual transaction prices, often lowering costs by 20-30% relative to AWP.
5. What is the outlook for Pemetrexed in emerging markets?
Emerging markets adopt generics more rapidly due to price sensitivity, leading to lower prices and increasing market share for biosimilars.
Sources
- IQVIA. (2023). Pharmaceutical Market Data.
- Eli Lilly. (2022). Alimta Sales Reports.
- EvaluatePharma. (2023). Global Oncology Market Forecast.
- FDA. (2022). Biosimilar Approval Announcements.
- Bright Research Group. (2023). Oncology Biosimilars Market Analysis.
